Mayzent tablets to treat relapsing multiple sclerosis have been approved by the FDA. But the treatment comes with a hefty price tag.
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
David Tepper's Appaloosa LP renews calls for changes at the top.
Johnson & Johnson received FDA approval for a nasal spray designed to treat patients with depression.
Eli Lilly shares traded lower Monday after it said it plans to launch a cut-price version of its top selling insulin treatment Humalog as pressure to lower drug costs continues to ripple through the pharmaceutical industry.
Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.
Strong sales of key cancer treatment drug Keytruda are expected to continue to drive revenues and earnings.
Analysts have noted that the weed leader's momentum is set to burn higher moving forward.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.